(Q53984577)
Statements
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. (English)
1 reference
1 reference
Charles Erlichman
1 reference
Jan C Buckner
1 reference
Marilyn S Pollack
1 reference
Joseph P Boni
1 reference
Gary Dukart
1 reference
Bonnie Marshall
1 reference
Lisa Speicher
1 reference
Laurence Moore
1 reference
Eric K Rowinsky
1 reference
1 October 2006
1 reference
12
1 reference
5755-5763
1 reference
19
1 reference
Identifiers
1 reference